CDx Diagnostics® is a unique medical technology company that has exclusive rights to a clinically-proven patented diagnostic platform for the enhanced detection of pre-cancer in the mouth, throat, and esophagus among other body sites.
Most cancers, including those of the mouth, throat, and gastrointestinal tract, are preceded by a pre-cancerous stage known as dysplasia. Dysplasia is the earliest form of pre-cancerous change in which abnormal cells are restricted to the epithelium and have not invaded through the basement membrane to the sub-mucosa. Identifying and removing dysplasias before they can progress to cancer has proven to be one of the most effective methods for reducing the incidence and mortality of cancer.
The CDx diagnostic platform combines a patented, minimally-invasive brush biopsy method of easily obtaining a complete tissue sample, and the use of sophisticated computer-assisted analysis of that brush biopsy sample to detect pre-cancerous cells.